ANDA 212957, held by Chartwell Rx. Fosaprepitant Dimeglumine.
As of Nov 15, 2026, ANDA 212957 (Fosaprepitant Dimeglumine), held by Chartwell Rx, was first approved by FDA on Aug 20, 2020, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 20, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fosaprepitant DimeglumineEQ 150MG BASE/VIAL ยท powder;intravenous | Fosaprepitant Dimeglumine | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
